Objectives and background: Introduction of tyrosine kinase inhibitor (TKI) for the treatment of
chronic myeloid leukemia (CML) led to favorable outcome in the majority of patients. About …

Background. About 70% of chronic myeloid leukemia (CML) patients achieve early
molecular response (BCR-ABL IS2 10% at 3-months) that lead to 5-years overall survival …

The BCR-ABL transcript level (≤ 10%) at 3 months after tyrosine kinase inhibitors can
predict long term outcome in the patients with chronic myeloid leukemia in chronic phase …

An early molecular response has a strong predictive value in chronic myeloid leukemia
(CML). Recently, the halving time (velocity of early BCR-ABL1 transcript elimination) has …

The present study aimed to assess the clinical impact of BCR‐ABL 1 transcript levels
determined at an earlier time point than the 3‐month early molecular response (EMR) in …

Abstract Abstract 3757 Background: Response to TKIs in CML at 3 month is a strong
predictor for long term outcome in CML patients treated with TKIs. Pts who do not achieve a …

Purpose: The early BCR-ABL1 reduction had the prognostic impact of the chronic-phase
chronic myeloid leukemia (CML-CP) patients. This study was to find a more precise early …

Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …

Background: The Canadian tyrosine kinase inhibitor (TKI) discontinuation trial, named
“Treatment Free Remission Accomplished By Dasatinib”(NCT# 02268370), has reported …

Several groups have shown that that the BCR-ABL1 transcript level measured at 3 or 6
months after starting treatment with tyrosine kinase inhibitors strongly predicts clinical …